Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorBermejo, Javier
dc.contributor.authorGonzález-Mansilla, Ana
dc.contributor.authorMombiela, Teresa
dc.contributor.authorFernández, Ana I.
dc.contributor.authorMartínez-Legazpi, Pablo
dc.contributor.authorYotti, Raquel
dc.contributor.authorEvangelista Masip, Artur
dc.date.accessioned2021-06-11T12:32:02Z
dc.date.available2021-06-11T12:32:02Z
dc.date.issued2021-01-19
dc.identifier.citationBermejo J, González‐Mansilla A, Mombiela T, Fernández AI, Martínez‐Legazpi P, Yotti R, et al. Persistent Pulmonary Hypertension in Corrected Valvular Heart Disease: Hemodynamic Insights and Long‐Term Survival. J Am Heart Assoc. 2021 Jan 19;10(2):e019949.
dc.identifier.issn2047-9980
dc.identifier.urihttps://hdl.handle.net/11351/6056
dc.descriptionHeart failure; Pulmonary hypertension; Valvular heart disease
dc.description.abstractBackground The determinants and consequences of pulmonary hypertension after successfully corrected valvular heart disease remain poorly understood. We aim to clarify the hemodynamic bases and risk factors for mortality in patients with this condition. Methods and Results We analyzed long‐term follow‐up data of 222 patients with pulmonary hypertension and valvular heart disease successfully corrected at least 1 year before enrollment who had undergone comprehensive hemodynamic and imaging characterization as per the SIOVAC (Sildenafil for Improving Outcomes After Valvular Correction) clinical trial. Median (interquartile range) mean pulmonary pressure was 37 mm Hg (32–44 mm Hg) and pulmonary artery wedge pressure was 23 mm Hg (18–26 mm Hg). Most patients were classified either as having combined precapillary and postcapillary or isolated postcapillary pulmonary hypertension. After a median follow‐up of 4.5 years, 91 deaths accounted for 4.21 higher‐than‐expected mortality in the age‐matched population. Risk factors for mortality were male sex, older age, diabetes mellitus, World Health Organization functional class III and higher pulmonary vascular resistance—either measured by catheterization or approximated from ultrasound data. Higher pulmonary vascular resistance was related to diabetes mellitus and smaller residual aortic and mitral valve areas. In turn, the latter correlated with prosthetic nominal size. Six‐month changes in the composite clinical score and in the 6‐minute walk test distance were related to survival. Conclusions Persistent valvular heart disease–pulmonary hypertension is an ominous disease that is almost universally associated with elevated pulmonary artery wedge pressure. Pulmonary vascular resistance is a major determinant of mortality in this condition and is related to diabetes mellitus and the residual effective area of the corrected valve. These findings have important implications for individualizing valve correction procedures.
dc.language.isoeng
dc.publisherWiley
dc.relation.ispartofseriesJournal of the American Heart Association;10(2)
dc.rightsAttribution-NonCommercial 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.sourceScientia
dc.subjectCor - Vàlvules - Malalties
dc.subjectHipertensió pulmonar - Factors de risc
dc.subject.meshHeart Valve Diseases
dc.subject.meshHypertension, Pulmonary
dc.subject.meshRisk Factors
dc.titlePersistent Pulmonary Hypertension in Corrected Valvular Heart Disease: Hemodynamic Insights and Long‐Term Survival
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1161/JAHA.120.019949
dc.subject.decsenfermedades de las válvulas cardíacas
dc.subject.decshipertensión pulmonar
dc.subject.decsfactores de riesgo
dc.relation.publishversionhttps://www.ahajournals.org/doi/10.1161/JAHA.120.019949
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Bermejo J, González-Mansilla A, Mombiela T, Fernández AI, Martínez-Legazpi P] Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Facultad de Medicina, Universidad Complutense de Madrid, and CIBERCV Madrid Spain. [Yotti R] Instituto de Salud Carlos III Madrid Spain. [Evangelista A] Vall d'Hebron Hospital Universitari, Barcelona, Spain. CIBERCV Barcelona, Spain
dc.identifier.pmid33399006
dc.identifier.wos000610049900028
dc.relation.projectidinfo:eu-repo/grantAgreement/ES/PE2017-2020/PI19%2F00649
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record